Beryl Drugs Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials

Quality Assessment: Weak Fundamentals Persist

Despite the recent upgrade, Beryl Drugs continues to exhibit weak long-term fundamental strength. The company reported flat financial performance in Q3 FY25-26, with net sales for the nine months ending December 2025 declining by 20.14% to ₹13.84 crores. Operating losses remain a concern, with PBDIT for the quarter at a negative ₹0.20 crores and PBT less other income at a low of ₹-0.61 crores. Over the past five years, net sales have grown at a modest annual rate of 10.21%, while operating profit has increased by only 5.06% annually, indicating sluggish growth.

Moreover, the company’s ability to service debt is weak, as reflected by an average EBIT to interest ratio of 0.75, signalling potential liquidity constraints. These factors contribute to a continued low Mojo Score of 31.0 and a Mojo Grade of Sell, albeit improved from the previous Strong Sell rating.

Valuation: Attractive but Risky

On the valuation front, Beryl Drugs presents a mixed picture. The company’s return on capital employed (ROCE) stands at 11%, which is relatively attractive within its peer group. Additionally, the enterprise value to capital employed ratio is a low 1.2, suggesting the stock is trading at a discount compared to historical valuations of its sector peers. This valuation discount may offer some appeal to value-oriented investors willing to tolerate operational risks.

However, the stock’s micro-cap status and weak financial fundamentals temper enthusiasm. Over the past year, while the stock price has generated a positive return of 5.76%, profits have declined by 7%, underscoring the disconnect between market performance and underlying earnings quality.

Financial Trend: Flat to Negative Performance

Beryl Drugs’ recent financial trends have been largely flat or negative. The company’s net sales for the nine months ended December 2025 fell sharply by 20.14%, while operating profits remain in the red. The quarterly PBDIT and PBT figures are at their lowest levels, indicating ongoing operational challenges. This flat financial performance contrasts with the company’s longer-term growth rates, which, although positive, remain modest and insufficient to inspire confidence in sustained profitability.

Despite these headwinds, the stock has outperformed the broader market indices in several time frames. Over the last one year, Beryl Drugs delivered a 5.76% return compared to the BSE500’s 2.02%. Over three and five years, the stock’s cumulative returns of 70.47% and 241.45%, respectively, have significantly outpaced the Sensex benchmarks of 24.71% and 50.25%. This market-beating performance suggests that investors may be pricing in potential recovery or sector-specific tailwinds.

Technicals: Improvement Drives Upgrade

The primary catalyst for the upgrade from Strong Sell to Sell is the improvement in technical indicators. The technical trend has shifted from bearish to mildly bearish, signalling a less negative momentum in the stock’s price action. Key technical metrics present a mixed but cautiously optimistic picture:

• MACD remains bearish on both weekly and monthly charts, indicating that momentum is still subdued.
• RSI shows no clear signal on weekly and monthly timeframes, suggesting a neutral momentum stance.
• Bollinger Bands are bullish on the weekly chart but mildly bearish monthly, reflecting short-term strength amid longer-term caution.
• Daily moving averages are mildly bearish, while Dow Theory signals are mildly bullish weekly but mildly bearish monthly.
• KST remains bearish on both weekly and monthly charts, and On-Balance Volume (OBV) data is inconclusive.

These technical nuances imply that while the stock is not yet in a strong uptrend, the worst of the bearish momentum may be abating. The recent sharp day change of 19.67% to close at ₹22.57, up from ₹18.86, supports this view of emerging positive price action.

Stock Price and Market Context

Beryl Drugs’ current price of ₹22.57 remains below its 52-week high of ₹30.00 but comfortably above the 52-week low of ₹15.92. The stock’s recent volatility, with intraday highs of ₹22.63 and lows of ₹18.51, reflects investor uncertainty amid mixed fundamentals and technical signals.

Majority shareholding remains with non-institutional investors, which may contribute to higher volatility and less predictable trading patterns. The company’s micro-cap status further accentuates this risk profile.

Summary and Outlook

Beryl Drugs Ltd’s upgrade from Strong Sell to Sell reflects a cautious improvement in technical indicators amid persistent fundamental weaknesses. The company’s flat financial performance, operating losses, and weak debt servicing capacity continue to weigh on its quality grade. However, attractive valuation metrics and a recent positive shift in technical trends provide some grounds for tempered optimism.

Investors should weigh the company’s micro-cap risks and operational challenges against its market-beating returns over the medium to long term. The stock’s recent price momentum and valuation discount may appeal to speculative investors, but the lack of robust earnings growth and ongoing losses suggest a need for prudence.

Overall, Beryl Drugs remains a speculative proposition within the Pharmaceuticals & Biotechnology sector, with the recent rating upgrade signalling a potential bottoming out of its downtrend rather than a definitive turnaround.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →